Impella in killip class IV acute myocardial infarction complicated by pulseless ventricular arrhythmia
Cardiovascular Intervention and Therapeutics · 2026-07 · 41 (3) · 609-617
DOI: 10.1007/s12928-026-01260-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Intervention and Therapeutics, online erschienen am 28.03.2026. Verfasst von Hajime Fujimoto und 21 weiteren Autor:innen. Beteiligte Einrichtung: Tokyo CCU Network Scientific Committee, Tokyo, Japan. fujimotoha0622@gmail.com. Hauptthemen laut MEDLINE: Myocardial Infarction, Tachycardia, Ventricular, Ventricular Fibrillation, Shock, Cardiogenic. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Mortality in acute myocardial infarction (AMI) complicated by cardiogenic shock remains high, particularly when accompanied by pulseless ventricular tachycardia (VT) or ventricular fibrillation (VF). The Impella device, a percutaneous mechanical circulatory support system that unloads the left ventricle, is increasingly used in AMI with shock. However, its impact on outcomes in patients with cardiogenic shock complicated by pulseless VT/VF remains unclear. We retrospectively analyzed Killip class IV AMI patients who developed pulseless VT/VF, using data from the Tokyo CCU Network registry (January 2019–December 2022). The primary endpoint was 30-day mortality. Outcomes in patients treated with Impella were compared with those without Impella using propensity score matching. Multivariate analysis was performed to identify independent predictors of mortality. Among 18,310 AMI patients, 1,986 were classified as Killip IV, of whom 715 developed pulseless VT/VF. Crude 30-day mortality did not differ significantly between the Impella and non-Impella groups (33.6% vs. 38.8%, p = 0.28). After propensity score matching, mortality was significantly lower in the Impella group (33.9% vs. 48.8%, p = 0.019). Multivariate analysis confirmed Impella use as an independent predictor of reduced mortality (odds ratio 0.32, 95% CI 0.19–0.56, p < 0.0001). Deaths due to VT/VF were less frequent in the Impella group (0.82% vs. 6.4%, p = 0.0030). In Killip IV AMI patients complicated by pulseless VT/VF, Impella use was associated with significantly lower 30-day mortality. These findings support early consideration of Impella in this high-risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Tokyo CCU Network Scientific Committee, Tokyo, Japan. fujimotoha0622@gmail.com.
- Department of Cardiology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan. fujimotoha0622@gmail.com.
- Tokyo CCU Network Scientific Committee, Tokyo, Japan.
Zitieren
APA
Fujimoto, H., Komiyama, K., Kodera, S., Kodama, T., Asano, T., Wakabayashi, K., Mase, T., Miyachi, H., Kishi, M., Yamashita, J., Miura, M., Saji, M., Mitsuhashi, Y., Ito, R., Kondo, S., Oomiya, J., Matsumoto, H., Miyauchi, K., Shinke, T., …, & Takayama, M. (2026). Impella in killip class IV acute myocardial infarction complicated by pulseless ventricular arrhythmia. Cardiovascular Intervention and Therapeutics, 41(3), 609-617. https://doi.org/10.1007/s12928-026-01260-8
Vancouver
Fujimoto H, Komiyama K, Kodera S, Kodama T, Asano T, Wakabayashi K, et al. Impella in killip class IV acute myocardial infarction complicated by pulseless ventricular arrhythmia. Cardiovascular Intervention and Therapeutics. 2026;41(3):609-617. doi:10.1007/s12928-026-01260-8
BibTeX
@article{Fujimoto2026,
author = {Fujimoto, Hajime and Komiyama, Kota and Kodera, Satoshi and Kodama, Takahide and Asano, Taku and Wakabayashi, Kohei and Mase, Takaaki and Miyachi, Hideki and Kishi, Mikio and Yamashita, Jun and Miura, Mizuki and Saji, Maiku and Mitsuhashi, Yuya and Ito, Ryosuke and Kondo, Seita and Oomiya, Jo and Matsumoto, Hidenari and Miyauchi, Katsumi and Shinke, Toshiro and Yamamoto, Takeshi and Kohsaka, Shun and Takayama, Morimasa},
title = {Impella in killip class IV acute myocardial infarction complicated by pulseless ventricular arrhythmia},
journal = {Cardiovascular Intervention and Therapeutics},
year = {2026},
volume = {41},
number = {3},
pages = {609--617},
doi = {10.1007/s12928-026-01260-8}
}
EUVIMED